U. at Buffalo participates in trial of drug derived from bat saliva

02/24/2010 | American City Business Journals

The University at Buffalo's Department of Neurology and the Jacobs Neurological Institute received approval to enroll patients in a clinical trial of desmosteplase, a drug candidate for acute ischemic stroke that was derived from a bioengineered protein in vampire bats' saliva. The study is part of a worldwide trial spearheaded by Lundbeck.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD